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Abstract
Enterococcus is an important cause of bacteraemia. Previous epidemiological studies examining risk factors for enterococcal bacteraemia
have used traditional case–control study designs, which can be potentially biased. This case–case–control study examining risk factors
for enterococcal bacteraemia was conducted over 10 years (January 2000 to December 2009) in a tertiary, university-affiliated hospital.
There were 440 episodes of enterococcal bacteraemia, 80 of which were caused by vancomycin-resistant Enterococcus (VRE). Two mul-
tivariable models were generated, comparing VRE and vancomycin-susceptible Enterococcus (VSE) with the same control group. VRE
bacteraemia was associated with central venous catheter use (OR 11.6, 95% CI 2.6–51.5), neutropenia (OR 16.9, 95% CI 2.4–120.2),
and allogenic bone marrow transplantation (OR 18.0, 95% CI 2.4–133.4). In contrast, VSE bacteraemia risk factors included: age
(OR 1.0, 95% CI 1.0–1.1), exposure to metronidazole (OR 8.7, 95% CI 1.7–43.5), and gastrointestinal disease (OR 6.4, 95% CI 1.2–
34.5). Meropenem use decreased the risk of VSE bacteraemia (OR 0.3, 95% CI 0.1–0.9). Hypoalbuminaemia was the only factor identi-
fied in both models (VRE, OR 6.0, 95% CI 1.7–21.1; VSE, OR 3.3, 95% CI 1.4–7.7). The absence of substantial overlap of risk factors
for VRE and VSE argues in favour of differences in pathogenesis. These data suggest that environmental sources are more important in
VRE bacteraemia. Endogenous sources, particularly the gastrointestinal tract, play a pivotal role in VSE bacteraemia. This study highlights
the importance of infection control protocols to reduce the risk of VRE bacteraemia.
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Introduction
Enterococcus is an important nosocomial pathogen. It can be
a challenging organism to treat, owing to increasing antibiotic
resistance, in particular the emergence of vancomycin-resis-
tant Enterococcus (VRE) [1]. Enterococcal bacteraemia is
associated with significant patient morbidity; vancomycin
resistance has been shown to be an independent predictor
of mortality [2,3].
Epidemiological studies have identified risk factors for VRE
colonization, but few studies have investigated risk factors
for enterococcal bacteraemia. Studies on the delineation of
risk factors for enterococcal bacteraemia use traditional
case–control designs, comparing resistant and susceptible
phenotypes. This methodology is potentially flawed, as it is
subject to bias, particularly in overestimating the effect of
antibiotics. A case–case–control study design decreases the
bias resulting from antibiotic use, and allows more accurate
assessment of risk factors for the resistant phenotype
through differentiation between factors associated with sus-
ceptible and resistant phenotypes and those inherent to
infection with enterococci generally [4–6].
Methods
The aim of this study was to elucidate potential risk factors
for the development of enterococcal bacteraemia in a cohort
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of patients. A retrospective case–case–control study was
conducted at a major tertiary referral teaching hospital with
300 acute-care beds. Specialist services include trauma ser-
vices, heart and lung transplant, bone marrow transplant,
including allogeneic transplants, cystic fibrosis, burns, human
immunodeficiency virus/AIDS, and haemophilia. A case–case–
control study design was chosen as a means to identify risk
factors unique to the resistant phenotype in addition to risk
factors that are associated with enterococci in general [4].
The study population consisted of all patients admitted
between January 2000 and December 2009. The resistant
case group consisted of patients with one or more blood
cultures positive for VRE. The susceptible case group con-
sisted of patients who had at least one blood culture positive
for vancomycin-susceptible Enterococcus (VSE). Enterococcal
bacteraemia cases were identified by review of the microbi-
ology database of positive blood cultures. Patients were
counted only once in the analysis. The control subjects were
matched to the VRE cases and were selected from the hos-
pital admission database as the next patient admitted, for a
duration of >48 h, to the same unit as the VRE case during
the same month who did not develop enterococcal bactera-
emia. The VSE cases were also matched to the VRE cases
chronologically as the next patient appearing on the
microbiological database admitted to the same unit or to a
clinically similar unit. The same control group was used for
each case–control study. Cases and controls were selected
irrespective of VRE colonization status.
Screening for VRE via rectal swabs was performed on all
patients in a ward following the identification of VRE in a
patient on the ward. Further screening of patients on the
ward was undertaken if any ward screen was positive for
VRE. Patients colonized with VRE were placed in isolation
with contact precautions, with gloves but no gowns. Routine
screening of patients on admission was not undertaken.
Infection control procedures did not change throughout the
duration of the study.
Samples for anaerobic and aerobic blood culture were
obtained by venipuncture with aseptic techniques or through
a central venous device, and incubated in the BacT/ALERT
blood culture system (bioMe´rieux, Durham, NC, USA). Posi-
tive blood cultures were Gram-stained and subcultured onto
horse blood agar, MacConkey agar, and chocolatized horse
blood agar, and incubated at 35C in 5% CO2. Identification
and antibiotic susceptibility of isolates was performed with
VITEK 2 Compact (bioMe´rieux). Isolates were cultured on
VRE screening plates with brain–heart infusion and Mueller–
Hinton agar containing 6 lg/L vancomycin. In addition,
multiplex PCR testing for the presence of vanA and vanB was
performed on all enterococcal isolates. Testing for vanC with
PCR was performed until August 2008, as this was found to
be rare.
During the study period, pulsed-field gel electrophoresis
was performed when several patients were identified as hav-
ing VRE on the same ward at the same time (Peel T, Cheng
A, Spelman T, Huysmans M, Spelman D, unpublished data).
These results consistently demonstrated significant diversity
in restriction fragment length, with over 30 types being
described at our institution, suggesting that VRE is an ende-
mic, rather than an epidemic, problem.
A data collection spreadsheet was designed to document
potential risk factors for the development of enterococcal
bacteraemia identified from a literature review (Table S1). A
single trained researcher (T.P.) obtained all additional infor-
mation from careful review of each patient’s medical record.
The demographic data for cases and controls were com-
pared by using summary statistics. Descriptive analyses were
based on percentages and frequencies for categorical vari-
ables, and medians and interquartile ranges for continuous
variables. Continuous variables were assessed for skew. Con-
ditional logistic regression analysis was used to produce ORs
with 95% CIs for the association between each variable and
the presence or absence of a VRE bacteraemia and VSE bac-
teraemia. Two multivariable models were generated. Multi-
variable conditional logistic regression techniques were used
in assessment of risk factors, by adding, in forward substitu-
tion, factors identified as significant in the univariable analysis
(p <0.1), and risk factors previously identified in the pub-
lished literature or according to biological plausibility. For
conditional logistic multivariate models, model fit was
assessed by the link test and by assessing the model-
predicted outcomes against observed case status. An
assessment for co-linearity between dependent variables is
incorporated into the clogit module in Stata.
TABLE 1. Demographic characteristics
VRE cases
(n = 80)
VSE cases
(n = 80)
Controls
(n = 80)
Median age, years (IQR) 55.5 (40.5–66) 62.5 (46–75.5) 55.5 (40–65.5)
Sex, no. (%)
Male 51 (64) 49 (61) 51 (64)
Female 29 (36) 31 (39) 29 (36)
Unit of admission, no. (%)
Medical 71 (89) 68 (85) 68 (85)
Surgical 9 (11) 12 (15) 12 (15)
Median days from admission
until bacteraemia (IQR)
18 (11.5–26.5) 9 (0.5–19.5) –
Enterococcus spp., no. (%)
E. faecalis 4 (5) 56 (70) –
E. faecium 76 (95) 24 (30) –
VanA, no. (%) 1 (1) – –
VanB, no. (%) 79 (99) – –
IQR, interquartile range; VRE, vancomycin-resistant Enterococcus; VSE, vancomy-
cin-susceptible Enterococcus.
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TABLE 2. Univariable and multivariable analysis of vancomycin-resistant Enterococcus (VRE) bacteraemiaa
Cases (n = 80) Controls (n = 80)
Univariable Multivariable
OR p-value 95% CI OR p-value 95% CI
Age (years) 55.5 (40.5–66) 55.5 (40–65.5) 1.01 0.599 0.99–1.02
Sex, no. (%)
Male 51 (63.8) 49 (61.3) 0.89 0.739 0.47–1.72
Female 29 (36.2) 31 (38.7)
VRE colonization, no. (%)
No 56 (70.0) 72 (90.0) 5.00 0.003 1.71–14.63
Yes 24 (30.0) 8 (10.0)
Prior vancomycin exposure, no. (%)
No 17 (21.2) 48 (60.0) 4.44 <0.001 2.16–9.16
Yes 63 (78.8) 32 (40.0)
Prior ceftriaxone exposure, no. (%)
No 70 (87.5) 68 (85.0) 0.82 0.655 0.34–1.97
Yes 10 (12.5) 12 (15.0)
Prior ceftazidime exposure, no. (%)
No 73 (91.2) 78 (97.5) 3.50 0.118 0.73–16.85
Yes 7 (8.8) 2 (2.5)
Prior cefepime exposure, no. (%)
No 58 (72.5) 70 (87.5) 4.00 0.013 1.34–11.96
Yes 22 (27.5) 10 (12.5)
Prior ticarcillin–clavulanate exposure, no. (%)
No 64 (80.0) 71 (88.7) 2.16 0.117 0.82–5.70
Yes 16 (20.0) 9 (11.3)
Prior piperacillin–tazobactam exposure, no. (%)
No 52 (65.0) 63 (78.7) 2.83 0.028 1.18–7.19
Yes 28 (35.0) 17 (21.3)
Prior meropenem exposure, no. (%)
No 36 (45.0) 60 (75.0) 4.43 <0.001 1.95–10.05
Yes 44 (55.0) 20 (25.0)
Prior ciprofloxacin exposure, no. (%)
No 29 (36.2) 53 (66.2) 3.67 0.001 1.75–7.66
Yes 51 (63.8) 27 (33.8)
Prior metronidazole exposure, no. (%)
No 60 (75.0) 77 (96.2) 9.50 0.002 2.21–40.78
Yes 20 (25.0) 3 (3.8)
ICU admission, no. (%)
No 52 (65.0) 71 (88.7) 3.71 0.002 1.61–8.56
Yes 28 (35.0) 9 (11.3)
Central line, no. (%)
No 7 (8.8) 41 (51.2) 12.33 <0.001 3.80–40.00 11.58 0.001 2.60–51.50
Yes 73 (91.2) 39 (48.8)
Neutrophils, no. (%)
>500 · 106/L 33 (41.3) 58 (72.5) 9.33 <0.001 2.84–30.70 16.93 0.005 2.38–120.23
£500 · 106/L 47 (58.7) 22 (27.5)
Days of neutropeniab 11 (3–16) 5 (0–12) 1.01 0.570 0.97–1.05
Chemotherapeutic agent causing mucositis, no. (%)
No 42 (52.5) 61 (76.2) 4.80 0.001 1.83–12.58
Yes 38 (47.5) 19 (23.7)
Secondary infection, no. (%)
No 32 (40.0) 63 (78.8) 6.17 <0.001 2.60–14.61
Yes 48 (60.0) 17 (21.2)
IDC, no. (%)
No 46 (57.5) 64 (80.0) 3.25 0.004 1.47–7.18
Yes 34 (42.5) 16 (20.0)
TPN, no. (%)
No 56 (70.0) 72 (90.0) 3.67 0.005 1.49–9.04
Yes 24 (30.0) 8 (10.0)
Diabetes mellitus, no. (%)
No 65 (81.3) 65 (81.3) 1.00 1.000 0.43–2.31
Yes 15 (18.7) 15 (18.7)
Solid organ transplant, no. (%)
No 73 (91.3) 77 (96.2) 3.00 0.178 0.61–14.86
Yes 7 (8.7) 3 (3.8)
Gastrointestinal disease, no. (%)
No 71 (88.8) 77 (96.2) 4.00 0.080 0.85–18.84
Yes 9 (11.2) 3 (3.8)
Allogeneic transplant, no. (%)
No 62 (77.5) 72 (90.0) 3.00 0.033 1.09–8.25 18.00 0.005 2.43–133.42
Yes 18 (22.5) 8 (10.0)
Acute leukaemia, no. (%)
No 50 (62.5) 59 (73.8) 2.13 0.079 0.92–4.92
Yes 30 (37.5) 21 (26.2)
Underwent abdominal surgery, no. (%)
No 75 (93.7) 76 (95.0) 1.33 0.706 0.30–5.96
Yes 5 (6.3) 4 (5.0)
Chronic kidney disease (eGFR), no. (%)
‡60 mL/min 47 (58.8) 50 (62.5) 1.19 0.613 0.61–2.31
<60 mL/min 33 (41.2) 30 (37.5)
Albuminc, no. (%)
‡35 g/L 27 (33.8) 42 (55.3) 2.63 0.006 1.32–5.28 6.01 0.005 1.71–21.12
<35 g/L 53 (66.2) 35 (44.7)
eGFR, estimated glomerular filtration rate; ICU, intensive-care unit; IDC, indwelling urinary catheter; TPN, total parenteral nutrition.
aLikelihood ratio chi-squared test = 58.99. Probability > chi-squared = 0.001.
bAnalysed as continuous variable; median (IQR) given.
cMissing data in case and/or control group.
Values in parentheses indicate interquartile range.
Bold face indicate values that are significant (p <0.05).
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TABLE 3. Univariable and multivariable analysis of vancomycin-susceptible Enterococcus (VSE) bacteraemiaa
Cases (n = 80) Controls (n = 80)
Univariable Multivariable
OR p-value 95% CI OR p-value 95% CI
Age (years) 62.5 (46–75.5) 55.5 (40–65.5) 1.03 0.008 1.01–1.05 1.03 0.048 1.00–1.06
Sex, no. (%)
Male 51 (63.8) 49 (61.3) 0.89 0.732 0.45–1.74
Female 29 (36.2) 31 (38.7)
VSE colonization, no. (%)
No 73 (91.3) 72 (90.0) 0.88 0.796 0.32–2.41
Yes 7 (8.7) 8 (10.0)
Prior vancomycin exposureb,c, no. (%)
No 54 (68.4) 48 (60.0) 0.76 0.413 0.38–1.38
Yes 25 (31.6) 32 (40.0)
Prior ceftriaxone exposureb,c, no. (%)
No 63 (80.8) 68 (85.0) 1.4 0.416 0.62–3.15
Yes 15 (19.2) 12 (15.0)
Prior ceftazidime exposureb,c, no. (%)
No 75 (96.2) 78 (97.5) 1.5 0.657 0.25–8.98
Yes 3 (3.8) 2 (2.5)
Prior cefepime exposureb,c, no. (%)
No 70 (89.7) 70 (87.5) 0.89 0.808 0.34–2.30
Yes 8 (10.3) 10 (12.5)
Prior ticaracillin–clavulanate exposureb,c, no. (%)
No 61 (78.2) 71 (88.7) 2.33 0.082 0.90–6.07
Yes 17 (21.8) 9 (11.3)
Prior piperacillin–tazobactam exposureb,c, no. (%)
No 73 (93.6) 63 (78.7) 0.27 0.019 0.09–0.80
Yes 5 (6.4) 17 (21.3)
Prior meropenem exposureb,c, no. (%)
No 68 (87.2) 60 (75.0) 0.47 0.079 0.20–1.09 0.30 0.040 0.10–0.95
Yes 10 (12.8) 20 (25.0)
Prior ciprofloxacin exposureb,c, no. (%)
No 53 (68) 53 (66.2) 0.94 0.862 0.48–1.86
Yes 25 (32) 27 (33.8)
Prior metronidazole exposureb,c, no. (%)
No 62 (79.5) 77 (96.2) 5.33 0.008 1.55–18.30 8.69 0.008 1.74–43.45
Yes 16 (20.5) 3 (3.8)
ICU admission, no. (%)
No 54 (68.4) 71 (88.7) 3.29 0.006 1.41–7.66
Yes 25 (31.6) 9 (11.3)
Central line, no. (%)
No 30 (38.0) 41 (51.2) 1.71 0.109 0.87–3.31
Yes 49 (62.0) 39 (48.8)
Neutrophils, no. (%)
>500 · 106/L 66 (82.5) 58 (72.5) 0.53 0.151 0.23–1.26
£500 · 106/L 14 (17.5) 22 (27.5)
Days of neutropeniac 0 11 (3–16) 0.76 0.057 0.58–1.01
Chemotherapeutic agent causing mucositis, no. (%)
No 71 (89.9) 61 (76.2) 0.41 0.048 0.17–0.99
Yes 8 (10.1) 19 (23.7)
Secondary infection, no. (%)
No 47 (58.8) 63 (78.8) 2.78 0.009 1.30–5.95
Yes 33 (41.3) 17 (21.2)
IDC present, no. (%)
No 44 (55.7) 64 (80.0) 2.58 0.005 1.33–5.03
Yes 35 (44.3) 16 (20.0)
TPN, no. (%)
No 64 (81.0) 72 (90.0) 2.33 0.082 0.90–6.07
Yes 15 (19.0) 8 (10.0)
Diabetes mellitus, no. (%)
No 59 (74.7) 65 (81.3) 1.67 0.226 0.73–3.81
Yes 20 (25.3) 15 (18.7)
Solid organ transplant, no. (%)
No 79 (98.8) 77 (96.2) 0.33 0.341 0.035–3.20
Yes 1 (1.2) 3 (3.8)
Gastrointestinal disease, no. (%)
No 63 (79.8) 77 (96.2) 7.50 0.007 1.72–32.80 6.39 0.031 1.19–34.45
Yes 16 (20.2) 3 (3.8)
Allogeneic transplant, no. (%)
No 72 (90.0) 72 (90.0) 1.00 1.00 0.38–2.66
Yes 8 (10.0) 8 (10.0)
Acute leukaemia, no. (%)
No 67 (83.8) 59 (73.8) 0.47 0.096 0.19–1.14
Yes 13 (16.2) 21 (26.2)
Underwent abdominal surgery, no. (%)
No 67 (83.5) 76 (95.0) 3.25 0.039 1.06–9.97
Yes 13 (16.5) 4 (5.0)
Chronic kidney disease (eGFR), no. (%)
‡60 mL/min 41 (51.3) 50 (62.5) 1.56 0.163 0.83–2.93
<60 mL/min 39 (48.7) 30 (37.5)
Albuminb, no. (%)
‡35 g/L 21 (26.3) 42 (55.3) 3.00 0.002 1.52–5.94 3.26 0.007 1.39–7.66
<35 g/L 59 (73.7) 35 (44.7)
eGFR, estimated glomerular filtration rate; ICU, intensive-care unit; IDC, indwelling urinary catheter; TPN, total parenteral nutrition.
aLikelihood ratio chi-squared test = 38.20. Probability > chi-squared = 0.001.
bMissing data in case and/or control group.
cAnalysed as continuous variable; median (IQR) given.
Values in parentheses indicate interquartile range.
Bold face indicate values that are significant (p <0.05).
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All reported p-values were two-tailed, and for each analy-
sis p <0.05 was considered to be significant. All analyses
were performed with Stata 10.1 (StataCorp, College Station,
TX, USA).
Results
Between January 2000 and December 2009, there were 440
episodes of enterococcal bacteraemia: 80 (18%) cases of VRE
bacteraemia, and 360 (82%) cases of VSE bacteraemia. The
basic demographic characteristics of cases and controls are
shown in Table 1. In VRE bacteraemia, Enterococcus faecium
was the most common isolate (91%), in contrast to VSE bac-
teraemia, where three-quarters of the isolates were Entero-
coccus faecalis. There was only one VRE isolate with a vanA
genotype, consistent with other epidemiological studies in
Australia [7]. The majority of patients with VRE bacteraemia
were admitted to the haematology unit (69%), as compared
with only 14% of patients with VSE bacteraemia. The inci-
dence of VRE bacteraemia increased during the study period;
at the end of the study period, VRE accounted for over one-
third of all cases of enterococcal bacteraemia.
The results of the univariable and multivariable analysis for
VRE bacteraemia are shown in Table 2. In the univariable
analysis of VRE bacteraemia, the following factors were most
strongly associated with VRE bacteraemia as compared with
controls: central venous catheter use; neutropenia; secondary
infection; VRE colonization; exposure to chemotherapeutic
agents with a high risk of mucositis; exposure to antimicrobial
therapy in the preceding 30 days, including vancomycin, me-
ropenem, cefepime, ciprofloxacin, piperacillin–tazobactam,
and metronidazole; intensive-care unit admission; total paren-
teral nutrition; indwelling urinary catheter; allogeneic bone
marrow transplantation; and hypoalbuminaemia.
The results of the univariable and multivariable analysis of
VSE bacteraemia are shown in Table 3. In the univariable
analysis, the following factors were associated with VSE bac-
teraemia: age; prior gastrointestinal disease; intensive-care
unit admission; abdominal surgery; hypoalbuminaemia; sec-
ondary infection; indwelling urinary catheter; exposure to
piperacillin–tazobactam; metronidazole; and chemotherapeu-
tic agents.
In the multivariable analysis, four factors were indepen-
dently associated with VRE bacteraemia: allogenic bone mar-
row transplantation; neutropenia; central venous catheter
use; and hypoalbuminaemia. In the VSE multivariable analysis,
four factors were identified as independent predictors of
bacteraemia: use of metronidazole in the 30 days prior to
bacteraemia; underlying gastrointestinal disease; hypoalbumin-
aemia; and advancing age. Exposure to meropenem in the
30 days prior to bacteraemia was protective.
The mortality rate was significantly higher in the resistant
and susceptible analysis than in the control. The 30-day mor-
tality rate was 37.5% in VRE bacteraemia patients as com-
pared with 23.8% and 2.5% in VSE bacteraemia patients and
controls, respectively (p <0.001 for VRE and p 0.005 for
VSE).
Discussion
In this study, we have found that the clinical profile of
patients with VRE bacteraemia differs from that of those
with VSE bacteraemia. We hypothesize that ‘exogenous’
sources, such as the presence of a central line in susceptible
hosts (particularly those with neutropenia or allogeneic bone
marrow transplantation), play an important role in the patho-
genesis of VRE bacteraemia. In contrast, we postulate that
VSE bacteraemia is more likely to be endogenous, arising
particularly from the gastrointestinal tract in a different
patient population.
The association between central venous catheters and
bloodstream infections is well established, and has been spe-
cifically described for VRE bacteraemia [8,9]. These results
highlight the importance of the spread of VRE from environ-
mental surfaces via central venous catheters into the blood-
stream. It emphasizes the importance of infection control
practices to reduce the incidence of VRE bacteraemia [10].
This study found that patients with underlying haematolog-
ical conditions are particularly susceptible to VRE bactera-
emia. The association of neutropenia and VRE bacteraemia is
consistent with the current literature [11]. In patients with
allogeneic transplants, VRE bacteraemia has been identified
as a risk factor for mortality; however, this study is the first
to demonstrate that allogeneic transplantation increases the
risk of VRE bacteraemia [12]. Explanations for the associa-
tion with underlying haematological conditions include immu-
nosuppressive effects of the underlying disease and
chemotherapeutic treatment, disruption of normal gastroin-
testinal mucosal barriers, and immune dysregulation leading
to increased migration of bowel microorganisms into the
bloodstream [13].
Hypoalbuminaemia was the only factor identified in the
VRE and VSE cohorts. Similar findings have been described in
VRE bacteraemia, but no studies to date have implicated low
albumin levels in VSE bacteraemia [14]. The underlying path-
ogenesis of hypoalbuminaemia and enterococcal bacteraemia
may be multifactorial. A low level of albumin, as an acute-
phase reactant, may be a surrogate marker for the severity
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of underlying disease processes. Second, the immunosuppres-
sion associated with malnutrition may directly lead to an
inadequate immune response to bacteraemia. Finally, a low
albumin level may be a marker of leakage through damaged
gastrointestinal mucosa, with associated increased migration
of enteric microorganisms [14].
With regard to antibiotic exposure, it is interesting to
note that antibiotic usage was not an independent predictor
of VRE bacteraemia. Antibiotic use has previously been iden-
tified as a predisposing factor for VRE bacteraemia in case
studies using VSE patients as controls [9,15–17]. All of the
antibiotics were significant on univariable analysis of VRE
bacteraemia, but this was not borne out on multivariable
analysis; this suggests that the association between immuno-
suppression and antibiotic use may be a confounding factor.
This may also relate to the bias of case studies resulting
from the protective effect of antibiotics when the susceptible
phenotype is used as the control group [4,5]. In the analysis
of VSE bacteraemia, exposure to metronidazole and merope-
nem was identified in the multivariable analysis. Metronida-
zole exposure was associated with an increased risk of VSE
bacteraemia. This finding is supported by animal studies, and
may reflect alterations in the gastrointestinal microbial com-
munity following metronidazole exposure, particularly a
reduction in the number of anaerobic microorganisms and
subsequent overgrowth and increased translocation of other
bacteria, including enterococci [18]. In contrast, it is interest-
ing to note that meropenem use was protective against VSE
bacteraemia. The literature is conflicting on the activity
of meropenem against VSE (the majority of enterococci in
this study were E. faecalis). Whereas Endtz et al. found a
meropenem MIC90 of 32 mg/L, other investigators have
found a lower MIC90 of 8 mg/L [19–21].
Advancing age is recognized as risk factor for bacteraemia
and for poorer outcomes following enterococcal bacteraemia
[22–24]. This association may relate to the increasing
number of comorbidities, such as urinary and gastrointestinal
tract pathology, or it may be a marker of declining immune
function [24]. This is supported by the identification of
existing gastrointestinal disease as a risk factor for VSE
bacteraemia.
There are several limitations to this study. In all retro-
spective studies, there is a potential for variability in report-
ing of clinical data by clinicians. We attempted to minimize
bias, in particular the influence of antibiotic exposure, which
is a limitation of traditional case–control studies. However,
the likely colinearity between antibiotic exposure in haema-
tology patients limits our ability to draw definitive conclu-
sions on whether antibiotic use or immunosuppression is the
likely confounder. The definition for cases was the documen-
tation of blood cultures positive for Enterococcus as recorded
in the microbiological database; therefore, whether the infec-
tion was a primary bloodstream infection, a central line-asso-
ciated infection or bacteraemia secondary to infection at
another body site was not consistently documented. There
were more VSE bacteraemia episodes than VRE episodes;
therefore, given the a priori case selection methodology, the
VSE case group was limited to only 22% of the total VSE
incident cases. In addition, there were significant differences
in the causative species between the sensitive and resistant
phenotypes, with E. faecium being the cause of VRE bactera-
emia, and E. faecalis accounting for the majority of VSE
bacteraemias. Therefore, the differences observed could be
potentially attributed to the species. This was not specifically
examined, and warrants further investigation. Finally,
although we chose a control group that was representative
of patients in the same unit as cases, we were not able to
match or adjust for severity of illness or comorbidities other
than those listed.
We have found epidemiological risk factors that suggest
differences in the disease pathogenesis of VRE and VSE bac-
teraemia. This study has confirmed the importance of central
venous catheterization, neutropenia and allogeneic transplan-
tation in VRE bacteraemia. It has emphasized the importance
of age, gastrointestinal disease and metronidazole use as pre-
dictors of VSE bacteraemia. Hypoalbuminaemia was the only
risk factor identified in both analyses.
These data suggest that, in susceptible patients in hospitals
where VRE has become endemic, measures to reduce infec-
tion rates in central lines may be more effective than efforts
to reduce antibiotic use, while acknowledging that both are
important infection control interventions. However, further
interventional studies are required to confirm this radical
hypothesis.
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